BioInvent International AB (publ)
0H22.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.47B
Close$
Share Statistics
| Market cap | $2.47 Billion |
|---|---|
| Enterprise Value | $2.19 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.02 |
| Beta | 0.02 |
| Outstanding Shares | 66,055,932 |
Return
| Return on Equity | -157.75% |
|---|---|
| Return on Assets | -118.08% |
| Return on Invested Capital | -152.80% |
Valuation & Multiples
| P/E Ratio | -3.07 |
|---|---|
| PEG | 0.74 |
| Price to Sales | - |
| Price to Book Ratio | 11.14 |
| Enterprise Value to Revenue | 67.38 |
| Enterprise Value to EBIT | -4.38 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$10.82 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$8.01 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BioInvent International AB (publ)
108 employees
CEO: Martin Welschof BioInvent International AB (publ) is a clinical-stage Swedish company dedicated to discovering, researching, and developing immunomodulatory antibodies for global cancer treatment, with reach across Sweden, Europe, the United States, and...